The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

NCT05938712 · Recruiting

Last updated 2026-05-28

This clinical trial tests the effects of a combination of two diabetes medications in people who have received a kidney transplant.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2023-10 · est. completion 2028-03

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT05938712 ↗

Description as written by the study sponsor.

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Treatments tested

Dapagliflozin 10 MG also known as FARXIGA Drug

Semaglutide subcutaneous once weekly for 12 weeks.
Semaglutide, 1.0 mg/mL also known as OZEMPIC Drug

Dapagliflozin oral once daily for 12 weeks.

Main thing measured	Proximal tubular natriuresis with combination therapy
Sponsor	University Health Network, Toronto
Conditions studied	Kidney Transplant Recipients
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05938712 ↗